Portola Pharmaceuticals Presents New In Vitro Data | PTLA Message Board Posts

Portola Pharmaceuticals, Inc.

  PTLA website

PTLA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  6371 of 6389  at  7/8/2019 2:02:35 PM  by

docoftheforce


 In response to msg 6369 by  jaznblues
view thread

Re: Portola Pharmaceuticals Presents New In Vitro Data

UptoDate - which was s reference used by many physicians - still is recommending Andexxa OR PCC’s! This study should make these KOL’s change their recommendations. So a very important news release by PTLA.
Here is the actual current text from UpToDate:

●Life-threatening bleeding – For patients who are at imminent risk of death from bleeding associated with direct factor Xa inhibitor anticoagulation, we suggest andexanet alfa or an unactivated 4-factor PCC (table 3).
•Dosing for andexanet, at one of two dose levels based on dose and timing of the factor Xa inhibitor, is described below. (See 'Andexanet alfa' below.)
•Dosing for unactivated 4 factor PCC is 25 to 50 units/kg or fixed dose of 2,000 units, as discussed below. (See 'PCCs and aPCCs' below.)
There is insufficient evidence about risks and benefits to strongly favor either 4-factor PCC or andexanet over the other.


Well there is evidence now!

Doc


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 9     Views: 383
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2018 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...